Epigenomics AG Fundamental Analysis (XETRA: ECX.DE)
Epigenomics AG Fundamental Analysis (XETRA: ECX.DE)
Epigenomics AG (XETRA: ECX.DE) shows weak financial fundamentals with a PE ratio of -2.43, profit margin of -13.08%, and ROE of -314.00%. The company generates $0.0B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of -40476.3/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze ECX.DE's fundamental strength across five key dimensions:
Efficiency Score
WeakECX.DE struggles to generate sufficient returns from assets.
Valuation Score
ExcellentECX.DE trades at attractive valuation levels.
Growth Score
WeakECX.DE faces weak or negative growth trends.
Financial Health Score
ModerateECX.DE shows balanced financial health with some risks.
Profitability Score
WeakECX.DE struggles to sustain strong margins.
Key Financial Metrics
Is ECX.DE Expensive or Cheap?
P/E Ratio
ECX.DE trades at -2.43 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, ECX.DE's PEG of -0.02 indicates potential undervaluation.
Price to Book
The market values Epigenomics AG at 383.68 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 32.44 times EBITDA. This signals the market has high growth expectations.
How Well Does ECX.DE Make Money?
Net Profit Margin
For every $100 in sales, Epigenomics AG keeps $-13.08 as profit after all expenses.
Operating Margin
Core operations generate -13.88 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-314.00 in profit for every $100 of shareholder equity.
ROA
Epigenomics AG generates $-2.70 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Epigenomics AG generates limited operating cash flow of $-5.70M, signaling weaker underlying cash strength.
Free Cash Flow
Epigenomics AG generates weak or negative free cash flow of $-5.70M, restricting financial flexibility.
FCF Per Share
Each share generates $-6.51 in free cash annually.
FCF Yield
ECX.DE converts -7.31% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-2.43
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.02
vs 25 benchmark
P/B Ratio
Price to book value ratio
383.68
vs 25 benchmark
P/S Ratio
Price to sales ratio
32.57
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
5690.50
vs 25 benchmark
Current Ratio
Current assets to current liabilities
110.25
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-314.00
vs 25 benchmark
ROA
Return on assets percentage
-0.03
vs 25 benchmark
ROCE
Return on capital employed
-0.03
vs 25 benchmark
How ECX.DE Stacks Against Its Sector Peers
| Metric | ECX.DE Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -2.43 | 31.29 | Better (Cheaper) |
| ROE | -31400.00% | 543.00% | Weak |
| Net Margin | -1308.33% | 8965.00% | Weak |
| Debt/Equity | 5690.50 | 0.51 | Weak (High Leverage) |
| Current Ratio | 110.25 | 5.79 | Strong Liquidity |
| ROA | -2.70% | -96.00% (disorted) | Weak |
ECX.DE outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Epigenomics AG's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation